Mid-term syllabus of Biochem-403: Introduction to Biosafety, Laboratory hazards, Biosafety levels of research laboratories, Good laboratory practices, International rules & regulations for  Biosafety, GMOs handling, Laboratory acquired infections and their transmission routs, Bio waste disposal,

…. PLUS…. First 150 MCQs from chapters 3 of the book ” MCQs in Biochemistry”. MCQs from the taught concepts and book chapters will also appear in the exam.

Final exam Biochem-403: Introduction to bioethics, GMOs related ethics, Ethical issues related to reproductive & cloning technologies, Role of institutional bioethical committees. 

…. PLUS…. First 150 MCQs from chapters 3 of the book ” MCQs in Biochemistry”. MCQs from the taught concepts and book chapters will also appear in the exam.

Start preparing your presentations and assignments…..  The presentations will be started right after the mid-term exam.

NO EXCUSE WILL BE ACCEPTED

__________________________________________________________________________________

Objective questions will be from the lectures, manuals, and books uploaded on this web-page.

 

                                                        __________________________________________________________________________________

Assignments and presentations: 

  1. The weightage of the assignment and presentation will be decided later. 
  2. Start preparing your presentations and assignments.
  3. The presentations will also be started right after the mid-term exam.
  4. PPT file should not contain any designing/colours other than figures and diagrams.
  5. Slides should be in 16X9 ratio.
  6. Fonts of all header should be same and of all other text should be same. 
  7. For detailed guidelines about the presentation of research article, visit: https://www.lifesciencesorg.combiochem-720/
  8. Download the template ppt file to make your presentation. The link is here (copy this link and paste in a new tab).
  9. Strictly follow the ppt format and it is better if you write and paste your material in the same ppt file.

K. General Question to be asked during the presentation

  1. 1) Pathway or importance of gene/technology/discovery
  2. 2) Rationale
  3. 3) Conclusion of the full article
  4. 4) Conclusion of every figure
  5. 5) New findings presented in the article
  6. 6) Applications of the findings
  7. 7) Future prospective
  8. 8) Applications of the work
  9. 9) Principle of every technique used in the research article

Moreover, provide me a printed summary of your article containing the above headings given under ‘K’.

L. During Presentations, for EVERY FIGURE and graph, we may ask:

1. The Principle of the experiment.
2. The Reason for doing the experiment/s.
3. The Physiological importance of the figure.
4. The Conclusions of the figure
5. Prepare well objectively and subjectively

______________________________________________________________________________ 

Microsoft teams will be used whenever online classes will be held. You must make your first name as your registration number. 

2017-ag-9382 Haidar Iftikhar

2017-ag-10077 Ahmad Faraz

______________________________________________________________________________

Microsoft Teams link for classes is given below:

https://teams.microsoft.com/l/meetup-join/19:[email protected]/1662975049970?context=%7B%22Tid%22:%2275df096c-8b72-48e4-9b91-cbf79d87ee3a%22,%22Oid%22:%22c066ef7d-a967-4f2e-b3ad-08e007c9866c%22%7D

BIOCHEM-403               BIOSAFETY AND ETHICS                              3(3-0)

Objectives

  • Introduce the biosafety regulations and ethical concepts in research
  • Emphasize on intellectual property rights issues and need for knowledge in patents.
  • Apply the concepts of biosafety and better communicate risk management to the public

Theory

Introduction to Biosafety, Laboratory hazards, Biosafety levels of research laboratories, Good laboratory practices, International rules & regulations for  Biosafety, GMOs handling, Laboratory acquired infections and their transmission routs, Bio waste disposal, Introduction to bioethics, GMOs related ethics, Ethical issues related to reproductive & cloning technologies, Role of institutional bioethical committees.

Suggested Readings

  1. Dawn P. Wooley, Karen B. Byers. Biological Safety: Principles and Practices, 5th Edition.2017. ASM Press.
  2. Department of Health and Human Services. Biosafety in Microbiological and Biomedical Laboratories. 5th Edition.2016. LULU Press.
  3. Goel and Parashar. IPR Biosafety and Bioethics. Kindle Edition.2013. Pearson Education.  
  4. Bioethics & Biosafety in Biotechnology by V Sree Krishna. 2011.New Age International Limited Publishers
  5. Laboratory Biosafety manual 3rd edition. WHO. 2006. AITBS publishers and distributors, India. 

Biochem-403, BS Biochem, 3rd, M-Winter 2023, Dr. Muhammad Ali; 28-08-2023

Sr.Ag No.Student’s NameGroupResearch article for presentation and 1 page summary
12022-ag-5240TAFSEELA AMJADG1A patch of positively charged residues regulates the efficacy of clinical DR5 antibodies in solid tumors
22022-ag-5241ALISHA 
32022-ag-5242ANSA BIBI
42022-ag-5243HADIA UMAR
52022-ag-5244MARYAM KHALIL
62022-ag-5245AHMAD HASSAN TARIQ
72022-ag-5246ESHA ARSHAD
82022-ag-5247Asma Nasir
92022-ag-5248FARIA NAWAZ
102022-ag-5249ESHA TAHIR
112022-ag-5251SHAFA SAJJADG2Preclinical evaluation of a novel antibody-drug conjugate targeting DR5 for lymphoblastic leukemia therapy
122022-ag-5252QIRAT RAZZAQ
132022-ag-5253KASHAF ALAM
142022-ag-5254AISHA ALI
152022-ag-5255ZAINAB 
162022-ag-5256BUSHRA NOOR
172022-ag-5257MARIYAM
182022-ag-5258IQRA BATOOL
192022-ag-5259MANAHIL YOUNIS
202022-ag-5260KHUZAIMA NADEEMG3A highly stable human single-domain antibody-drug conjugate exhibits superior penetration and treatment of solid tumors
212022-ag-5261AYESHA NAVEED
222022-ag-5262FIZA FATIMA
232022-ag-5263VANEEZA AHMAD
242022-ag-5264HAFSA TAHIRA
252022-ag-5265MUHAMMAD MUZAMMAL IKRAM
262022-ag-5266MUHAMMAD BILAL
272022-ag-5267ABDUL HANNAN
282022-ag-5268FAIZA LARAIBG5Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1
292022-ag-5269SAHER FARAZ
302022-ag-5270MUHAMMAD USMAN 
312022-ag-5271MANAHIL MALIK
322022-ag-5272MAHEEN ASIF CHAUDHARY
332022-ag-5273ZAINAB 
342022-ag-5274MUNIM ALI
352022-ag-5276MUBASHAR ALI
362022-ag-5277MUHAMMAD SHAHBAZ JAMILG5Mesoporous Silica Nanoparticles as Drug Delivery Systems for Targeted Inhibition of Notch Signaling in Cancer
372022-ag-5278KISA FATIMA
382022-ag-5279MUHAMMAD MOHSIN RAZA
392022-ag-5280KASHAF FATIMA
402022-ag-5281LAIBA AZHAR
412022-ag-5282ANEELA SHAHZADI
422022-ag-5283RABIA RAMZAN
432022-ag-5284EMAN FATIMA
442022-ag-5285MARYAM SADDIQUAG6L-Arginine Modulates T Cell Metabolism and Enhances Survival and Anti-tumor Activity
452022-ag-5286ARIBA AKBAR
462022-ag-5287MARWA NADEEM
472022-ag-5288GHULAM HUSSAIN
482022-ag-5289SAMANIA KHALID
492022-ag-5292LUBABA SAEED
502022-ag-5293NIMRA EMAN 
512022-ag-5294RIZA SIKANDAR 
522022-ag-5295HAMNA IRSHADG7BMP4 Upregulation Is Associated with Acquired Drug Resistance and Fatty Acid Metabolism in EGFR-Mutant Non-Small-Cell Lung Cancer Cells
532022-ag-5296MARYAM HAMDA
542022-ag-5297MARYAM RANI
552022-ag-5298ALI 
562022-ag-5299HAIQA AKHTAR
572022-ag-5300SANAA ABBAS
582022-ag-5301ABDUL REHMAN
592022-ag-5302AIMAN HAMID
602022-ag-5303MARIAM FATIMA
612022-ag-5304MALAIKA NADEEMG8The topoisomerase inhibitor CPT-11 prevents the growth and metastasis of lung cancer cells in nude mice by inhibiting EGFR/ MAPK signaling pathway
622022-ag-5305MAMOONA
632022-ag-5306SABA JAVED
642022-ag-5307MARRIAM SALEEM
652022-ag-5308AFSHEEN QADRI
662022-ag-5309ITRAT FATIMA
672022-ag-5311MAHA
682022-ag-5312ZEESHAN ALI SHAHZAD
692022-ag-5313FARWA ASGHAR
702022-ag-5314UMER AKMALG9Identification of actionable targets for breast cancer intervention using a diversity outbred mouse model
712022-ag-5315TAYYABA EMAN
722022-ag-5316DANIYA PAKEEZA
732022-ag-5317TAYBA ALI HUSSAIN
742022-ag-5318AIMAN SHABBIR
752022-ag-5319TAYYABA NAVEED
762021-ag-7031AYESHA ASLAM
772022-ag-5320Fatima Idrees
782022-ag-5337ZAINAB G10ZNF451 favors triple-negative breast cancer progression by enhancing SLUG-mediated CCL5 transcriptional expression
792022-ag-5338Aliza Ahmad
812022-ag-5340Noor Bhari
822022-ag-5354Hira Fatima
832022-ag-5355Ifra Muzaffar
842022-ag-5361Tayyavba shaukat
852022-ag-5364Fatima Miraj
862022-ag-5365Sabahat Masood

 

Biosafety Cabinets- Definition, Classes (I, II, III) and Types (Link)

Add your first comment to this post

Comments are closed.